Dongyan Liu, MD
Hematology & Oncology · Frederick, MDNPI 1912391913
Payments from drug & device makers
Across 57 payments — averaging $65.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$2K
- Johnson & Johnson$245
- AstraZeneca$191
- Daiichi Sankyo Inc.$142
- Gilead$135
- Beigene USA, Inc.$134
- plus $1K from 23 others
What the payments were for
- Travel & lodging$1,21933%
- Food & beverage$2,50667%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 12 | $1,838 |
| Johnson & Johnson | 5 | $245 |
| AstraZeneca | 4 | $191 |
| Daiichi Sankyo Inc. | 2 | $142 |
| Gilead | 2 | $135 |
| Beigene USA, Inc. | 1 | $134 |
| Mirati Therapeutics, Inc. | 2 | $132 |
| Stemline Therapeutics Inc. | 1 | $131 |
| Eisai Inc. | 2 | $123 |
| Bristol Myers Squibb | 3 | $85 |
| Pfizer | 2 | $59 |
| AbbVie | 2 | $56 |
| Novartis | 2 | $48 |
| GSK | 2 | $38 |
| Bayer | 1 | $31 |
| Geron Corporation | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Myriad Genetic Laboratories, Inc. | 1 | $28 |
| Beone Medicines USA, Inc. | 1 | $27 |
| Pharmacosmos Therapeutics Inc. | 1 | $27 |
| Array Biopharma Inc | 1 | $27 |
| Tolmar, Inc. | 1 | $27 |
| Pharmaand GmbH | 1 | $27 |
| Exelixis Inc. | 1 | $27 |
| Merck | 1 | $25 |
| Caris MPI, Inc. | 1 | $21 |
| Tempus AI, Inc | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $16 |
| ADC Therapeutics America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,729 in reported general payments places this provider in the 40th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 20 | $310,908 |
| BrukinsaZanubrutinib | 24 | $278,245 |
| RevlimidLenalidomide | 12 | $218,761 |
| EliquisApixaban | 53 | $47,003 |
| XareltoRivaroxaban | 24 | $23,657 |
| Exemestane | 21 | $6,953 |
| Anastrozole | 75 | $2,341 |
| Letrozole | 30 | $1,631 |
| Potassium Chloride | 27 | $1,008 |
| Tamoxifen Citrate | 24 | $870 |
| Ondansetron Hcl | 59 | $341 |
| Prochlorperazine Maleate | 16 | $106 |
| Dexamethasone | 11 | $94 |
| Prednisone | 17 | $85 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $57 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $48 | $310,90820 claims |
| Beigene USA, Inc.Brukinsa | $134 | $278,24524 claims |
| Bristol Myers SquibbRevlimid | $85 | $218,76112 claims |
| PfizerEliquis | $59 | $47,00353 claims |
| Johnson & JohnsonXarelto | $245 | $23,65724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Frederick
- Sadaf TaimurFrederick$165K
- Robert KreitmanOlney$54.2M
- Ralph BocciaBethesda$12.1M
- Dan ZandbergBaltimore$9.9M
- Ani BalmanoukianBaltimore$6.6M
- Mark MarkowskiBaltimore$5.9M
- Giuseppe GiacconeBethesda$5.4M
- Ivana GojoBaltimore$5M
- Suman RaoBaltimore$4.2M
- Tim GretenBethesda$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.